Verona Pharma’s ensifentrine meets COPD objectives
20th December 2022 Uncategorised 0Therapy shows quality of life boost and significant improvement in lung function More: Verona Pharma’s ensifentrine meets COPD objectives Source: News
read moreTherapy shows quality of life boost and significant improvement in lung function More: Verona Pharma’s ensifentrine meets COPD objectives Source: News
read moreColoAlert research could identify advanced adenomas among colorectal cancer patients More: Mainz recruits first patient into biomarker research Source: News
read moreXeris gets green light to take subcutaneous challenger to AbbVie drug into phase 2 ntaylor Tue, 12/20/2022 – 06:35 More: Xeris gets green light to take subcutaneous challenger to AbbVie drug into phase 2 Source: fierce
read moreAtara makes history with world-first nod for allogeneic T-cell therapy Ebvallo fkansteiner Mon, 12/19/2022 – 14:06 More: Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo Source: fierce
read moreAbbVie’s Vraylar, carrying $4B sales target, wins FDA label expansion in depression zbecker Mon, 12/19/2022 – 11:13 More: AbbVie's Vraylar, carrying B sales target, wins FDA label expansion in depression Source: fierce
read moreNovartis prunes nearly 300 jobs in Garden State as corporate slimdown rolls on fkansteiner Mon, 12/19/2022 – 10:53 More: Novartis prunes nearly 300 jobs in Garden State as corporate slimdown rolls on Source: fierce
read more© 1994 - 2024 B.M. Pharmaceuticals